Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Octreotide-induced thrombocytopenia: a case report.

Armin Rashidi1, Nahid Rizvi

  • 1Department of Internal Medicine, Eastern Virginia Medical School, 825 Fairfax Avenue, Suite 410, Norfolk, VA 23507, USA. rashida@evms.edu.

Journal of Medical Case Reports
|July 7, 2011
PubMed
Summary

Octreotide therapy can cause a rare but serious drop in platelet count (thrombocytopenia), especially during esophageal variceal bleeding. This case shows the condition is reversible upon discontinuing the medication.

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cohesive modules of engraftment in fecal microbiota transplantation.

iScience·2026
Same author

Differential effects of two common GVHD prophylaxis regimens on the gut microbiome: Results from the BMT CTN 1801 study.

bioRxiv : the preprint server for biology·2026
Same author

Longitudinal Multicompartment Oral Mucositis Assessment in Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation: A Contemporary Prospective Cohort Analysis.

Transplantation and cellular therapy·2026
Same author

Successful Treatment of Steroid-refractory Acute Graft-versus-host Disease With Ruxolitinib in a Liver Transplant Recipient.

Transplantation·2025
Same author

Antibiotic risk score for acute graft-versus-host disease.

Blood advances·2025
Same author

Dental plaque microbiota following allogeneic hematopoietic cell transplantation and risk of chronic graft-<i>versus</i>-host disease.

Haematologica·2025

Area of Science:

  • Gastroenterology
  • Hematology
  • Pharmacology

Background:

  • Thrombocytopenia is a rare complication of octreotide therapy.
  • It can be life-threatening in patients with esophageal variceal bleeding.
  • Alcohol-induced cirrhosis is a relevant comorbidity.

Purpose of the Study:

  • To report a case of octreotide-induced reversible thrombocytopenia.
  • To highlight the potential for this adverse effect in patients with gastrointestinal bleeding.

Main Methods:

  • A case presentation of a 54-year-old male with alcohol-induced cirrhosis and upper GI bleeding.
  • Monitoring of platelet count following octreotide administration.
  • Observation of platelet count changes after drug discontinuation.

Related Experiment Videos

Main Results:

  • The patient's platelet count decreased significantly after starting octreotide.
  • Platelet count recovered quickly after octreotide was stopped.
  • The thrombocytopenia was determined to be reversible.

Conclusions:

  • Octreotide therapy can lead to thrombocytopenia, a rare but serious side effect.
  • Vigilance is required to identify this condition in patients undergoing octreotide treatment for variceal bleeding.
  • Early recognition and drug discontinuation facilitate recovery.